Tiba Biotech has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and Development Authority (‘BARDA’), to apply our next-generation nucleic acid delivery technology to develop new products that can guard against and respond to public health threats.
Tiba Biotech was mentioned in the recent edition of THE VIRAL MOST WANTED, a series of articles by the Coalition for Epidemic Preparedness Innovations (CEPI), highlighting progress toward the development of next generation flavivirus vaccines.
Tiba Biotech receives an NIH Phase II SBIR grant to continue its development of a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
This article, appearing in Scrip’s Tech Transfer Roundup, reports on Tiba Biotech and CEPI planning ahead for the next pandemic.
Pour nos ami(e)s francophones, voici un reportage sur le parteneriat entre CEPI et Tiba Biotech.
The partnership between CEPI and Tiba Biotech is the focus of this article in Science & Enterprise.
Precision Vaccinations reports on CEPI and Tiba Biotech’s partnership to evaluate next-generation RNA vaccine platform technology.
One of the UK’s leading daily newspapers, The Telegraph, reports on the partnership between CEPI and Tiba Biotech and that CEPI has invested in a project to develop cheaper, more effective shots with fewer side effects.
As the first award to be granted under CEPI’s innovation program, CEPI will provide US$2 million to advance Tiba Biotech’s novel RNA nanoparticle delivery platform, RNABL™.
In a study published in Science Immunology, University of Minnesota researchers in collaboration with colleagues at Tiba Biotech and Emory University, demonstrated that nasal delivery of Tiba's RNABL vaccine induced adaptive immune responses in the respiratory tracts of mice.
© 2024 Tiba Biotech LLC. All rights reserved
